Nachrichten zur Rhythm Pharmaceuticals Inc. Aktie

Rythm Pharmaceuticals (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million

Key PointsRythm Pharmaceuticals Chief Technical Officer, Joseph Shulman, recently exercised and sold some stock options. Shulman still held 8,509 shares…

Rhythm Pharmaceuticals kurz vor HO-Zulassung – Milliardenmarkt ohne ernsthafte Konkurrenz

Rhythm Pharmaceuticals steht mit Setmelanotid vor der ersten Zulassung für die seltene hypothalamische Adipositas – ein Milliardenmarkt mit kaum Konkurrenz. …

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript

…

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline

Rhythm Pharmaceuticals (RYTM) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

Should You Invest in This Under-the-Radar Weight Loss Stock?

Key PointsRhythm Pharmaceuticals lone approved product currently generates minimal sales.However, recent clinical progress could help change that in the coming…

Rhythm Pharmaceuticals CFO Sells 42,120 Shares

Smith Hunter C, Chief Financial Officer of Rhythm Pharmaceuticals(NASDAQ:RYTM), reported mixed transactions totaling 42,120 shares on July 9, 2025, as…

Rhythm Pharmaceuticals: Auf dem Weg zur Pionierrolle bei seltener Adipositas

Kursfeuerwerk nach Studiendaten: Rhythm überzeugt mit starken Phase-2-Ergebnissen für eine orale Adipositas-Therapie und katapultiert sich ins Blickfeld institutioneller Investoren. …

Rhythm Pharmaceuticals prices upsized public offering at $85 per share By Investing.com

Rhythm Pharmaceuticals prices upsized public offering at $85 per share…

RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data

Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study…

Rhythm Pharmaceuticals stock soars on positive Phase 2 obesity drug data By Investing.com

Rhythm Pharmaceuticals stock soars on positive Phase 2 obesity drug data…

Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know

Rhythm Pharmaceuticals (RYTM) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

Rhythm gelingt Durchbruch bei seltener Adipositas – Studienerfolg weckt Kursfantasie

• Studienerfolg mit IMCIVREE®: Rhythm erreicht Durchbruch bei bisher untherapierbarer Adipositas-Form – Zulassungsantrag für 2025 geplant. • Marktpotenzial & Expansion: Umsatz-Chance... …

RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study

Rhythm Pharmaceuticals stock gains 17% on meeting goals with statistical significance in the late-stage acquired hypothalamic obesity study for setmelanotide.…

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity

Company to host conference call on April 7 at 8 a.m. ET Company to host conference call on April 7…

Rhythm Pharmaceuticals reports preliminary Q4 IMCIVREE revenue $42M

…

Rhythm Pharmaceuticals: Jährliches Umsatzwachstum von fast 70 % durch Adipositas-Therapie

Viele Unternehmen im Megatrend Biopharmazeutika haben durch Donald Trumps Wahlsieg zum US-Präsidenten einen deutlichen Schub erhalten, doch zahlreiche Aktienkurse korrigierten…

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused…

Hungerkontrolle: Der Kampf gegen Adipositas

Rhythm Pharmaceuticals ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung innovativer Therapien zur Behandlung seltener genetischer Adipositasstörungen konzentriert. Das…